Last reviewed · How we verify
Intratracheal administration of surfactant
Intratracheal administration of surfactant is a Surfactant Small molecule drug developed by Chiesi Poland Sp. z o.o.. It is currently in Phase 2 development for Respiratory distress syndrome in preterm infants.
Surfactant replacement therapy
Surfactant replacement therapy Used for Respiratory distress syndrome in preterm infants.
At a glance
| Generic name | Intratracheal administration of surfactant |
|---|---|
| Sponsor | Chiesi Poland Sp. z o.o. |
| Drug class | Surfactant |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Intratracheal administration of surfactant to reduce surface tension in the lungs, facilitating gas exchange and improving lung function in preterm infants with respiratory distress syndrome.
Approved indications
- Respiratory distress syndrome in preterm infants
Common side effects
Key clinical trials
- Little Lungs Study (PHASE1, PHASE2)
- Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome (PHASE4)
- Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants (NA)
- To Investigate the Effect of Pulmonary Surfactant With Different Inspired Oxygen Concentrations on the Clinical Outcomes of Very Preterm Infants Under Non-invasive Assisted Ventilation (NA)
- Evaluation of Serial Lung Ultrasound Data After Surfactant Treatments Applied With Different Methods in Preterm Babies (NA)
- Surfactant Therapy Via Supraglottic Airway to Preterm Neonates With RDS in Vietnam (NA)
- Feasibility Study of Placement and Surfactant Administration Through a Preterm Size Laryngeal Mask Airway in Very Low Birth Weight Neonates With Respiratory Distress Syndrome (NA)
- Bedside Ultrasound to Monitor Lung Function and Blood Flow in Newborns Treated With Surfactant
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intratracheal administration of surfactant CI brief — competitive landscape report
- Intratracheal administration of surfactant updates RSS · CI watch RSS
- Chiesi Poland Sp. z o.o. portfolio CI
Frequently asked questions about Intratracheal administration of surfactant
What is Intratracheal administration of surfactant?
How does Intratracheal administration of surfactant work?
What is Intratracheal administration of surfactant used for?
Who makes Intratracheal administration of surfactant?
What drug class is Intratracheal administration of surfactant in?
What development phase is Intratracheal administration of surfactant in?
Related
- Drug class: All Surfactant drugs
- Manufacturer: Chiesi Poland Sp. z o.o. — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Respiratory distress syndrome in preterm infants
- Compare: Intratracheal administration of surfactant vs similar drugs
- Pricing: Intratracheal administration of surfactant cost, discount & access